Prevenar--pneumococcal conjugate vaccine.
While Prevenar (pneumococcal conjugate vaccine, 7 valent), the first and only pneumococcal conjugate vaccine to help protect infants and toddlers against the disease, is already available in South Africa, the majority of children are not being routinely protected against the potentially devastating consequences of the disease owing to it not currently being included in the national childhood immunisation programme.
Routine vaccination would not only help to reduce disease burden, but could also help to reduce public health costs. A recent pharmacoeconomic evaluation found that routine use of Prevenar in the USA not only helps prevent deaths from pneumococcal disease, but also reduces associated health care costs for patients and payers. This evaluation included both direct effect on routinely immunised children as well as indirect benefits for unvaccinated adults.
Adoption of the WHO policy in South Africa, in addition to broader adoption around the world, has the potential to save millions of children's lives and is a vital step towards achieving the United Nations Millennium Development Goal of reducing child mortality by two-thirds by 2015.
Enquiries: Dr Nini Ramasamy, Medical Director Wyeth Pharmaceuticals, tel (011) 655-2600. References available on request.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Pulse: The heartbeat of the marketplace|
|Publication:||CME: Your SA Journal of CPD|
|Article Type:||Brief article|
|Date:||Jul 1, 2007|
|Previous Article:||Prostate cancer in African men.|
|Next Article:||Mouthulcer and LipRevive cold sore capsules.|